Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A, Fraz MA, Usman M, Malik SU, Ijaz A, Durer C, Durer S, Tariq MJ, Khan AY, Qureshi A, Faridi W, Nasar A, Anwer F. Kumar A, et al. Curr Treat Options Oncol. 2018 Sep 1;19(10):50. doi: 10.1007/s11864-018-0565-6. Curr Treat Options Oncol. 2018. PMID: 30173370 Review.
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD, Guillen-Rodriguez J, Kumar A, Inclán L, Heard K, Rivera XI, Anwer F, Schatz JH, Mahadevan D, Persky DO. Puvvada SD, et al. Among authors: kumar a. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):58-64. doi: 10.1016/j.clml.2017.09.001. Epub 2017 Sep 19. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29056470 Clinical Trial.
Treatment of Early (Limited)-Stage DLBCL.
Kumar A, Persky DO. Kumar A, et al. Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S34-S36. doi: 10.1016/S2152-2650(20)30454-7. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32862861 No abstract available.
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
Moore L, Bartels T, Persky DO, Abraham I, Kumar A, McBride A. Moore L, et al. Among authors: kumar a. Support Care Cancer. 2021 Aug;29(8):4867-4874. doi: 10.1007/s00520-020-05982-0. Epub 2021 Feb 6. Support Care Cancer. 2021. PMID: 33547525
Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S, Kumar A, Korde N, Agarwal A. Sundararajan S, et al. Among authors: kumar a. Curr Hematol Malig Rep. 2016 Apr;11(2):102-10. doi: 10.1007/s11899-016-0305-6. Curr Hematol Malig Rep. 2016. PMID: 26894382 Review.
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
Sancho JM, Abrisqueta P, Kumar A, Cordoba R, Tani M, Langmuir P, Rappold E, Liu T, Lopez-Guillermo A. Sancho JM, et al. Among authors: kumar a. Leuk Lymphoma. 2024 Jul;65(7):911-921. doi: 10.1080/10428194.2024.2331626. Epub 2024 Apr 10. Leuk Lymphoma. 2024. PMID: 38598516 Clinical Trial.
31,758 results
You have reached the last available page of results. Please see the User Guide for more information.